How Much Weight Can You Lose on Tirzepatide?

"How much weight can you lose on tirzepatide?" is one of the most searched questions about this compound, and the honest answer is a range, not a single number. Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in the SURMOUNT clinical trial program, and those trials reported average weight change by dose over fixed time periods. This page summarizes those published averages, the typical timeline to a plateau, and what the data shows for people whose results come in slowly.

This is general reference information drawn from published research, not medical or dosing advice. Averages from a controlled trial are not a prediction for any individual, and tirzepatide is a research compound not approved for casual use. Decisions about whether it is appropriate, at what dose, and for how long belong to a licensed clinician. To map any dose to the units on your syringe, use the tirzepatide calculator.

SURMOUNT-1 averages by dose

SURMOUNT-1 was a 72-week trial in adults with obesity (without diabetes) that tested three weekly maintenance doses against placebo, alongside lifestyle changes. The headline figures most people quote come from this trial. Reported average total body weight reduction at 72 weeks was roughly:

• 5 mg weekly: about 15% average body weight reduction
• 10 mg weekly: about 19.5% average body weight reduction
• 15 mg weekly: about 20.9% average body weight reduction
• Placebo: about 3.1% average body weight reduction

Put in pounds, a person starting at 230 lb who tracked the 15 mg average would see roughly a 48 lb change over 72 weeks (230 x 0.209). At the 5 mg average it would be closer to 35 lb (230 x 0.15). The same percentages applied to a 180 lb starting weight give roughly 38 lb and 27 lb. The percentage is what the trial measured; the pounds depend entirely on starting weight.

Why the dose matters

The trial data shows a clear dose-response pattern: higher maintenance doses were associated with larger average reductions. But the gap narrows at the top. Moving from 5 mg to 10 mg added roughly 4.5 percentage points on average, while moving from 10 mg to 15 mg added only about 1.4. That flattening is one reason a clinician may hold someone at a middle dose rather than pushing to the ceiling. Tolerability, side effects, and individual response all factor into where a dose lands, which is a clinical decision, not a math one. For how doses step up over time, see the tirzepatide dosage chart.

The timeline and the plateau

Weight change on tirzepatide in the trials was not linear. The curve was steepest in the early months while the dose was still climbing, then gradually flattened. A rough picture of the SURMOUNT-1 trajectory:

• Weeks 0 to 20: the titration phase, with weight coming off fastest as the dose steps up
• Weeks 20 to 52: a steady decline at the maintenance dose
• Weeks 52 to 72: the curve flattens as the average approaches its plateau

Most of the average reduction had accumulated by around the one-year mark, with the final months adding smaller increments. A plateau in the data does not mean nothing is working; it means the body has reached a new steady state at that dose. For how long the compound takes to show measurable change, see how long tirzepatide takes to work.

Late responders and the response spread

Averages hide a wide spread. In SURMOUNT-1, the share of participants reaching key thresholds at 15 mg was striking: roughly 91% reached at least 5% reduction, about 83% reached 10% or more, around 71% reached 15% or more, and roughly half reached 20% or more. That spread means some people far exceeded the average and others fell well short of it on the same dose.

It also means a slow start is not the end of the story. Some participants showed limited change in the first weeks and then continued losing through the back half of the trial. Because the dose climbs gradually during titration, the early weeks at 2.5 mg and 5 mg are not where the trial saw its largest effects. A flat scale at week 8 is not the same as a flat scale at week 40. Whether to wait, adjust, or stop is a conversation for a clinician, not a decision to make from a search result.

Reading the numbers against your own vial

Trial doses are stated in milligrams, but a syringe reads in units, and the conversion depends on how the vial was reconstituted. A 30 mg vial mixed with 3 mL of bacteriostatic water gives 10 mg/mL, so 5 mg is 50 units and 15 mg is 150 units (more than one U-100 syringe). Change the water volume and every number shifts. Run your own vial through the tirzepatide calculator, or start upstream with the reconstitution calculator to lock in your concentration first. For context on how tirzepatide compares to a single-agonist option, see semaglutide vs tirzepatide.

The bottom line: published trial averages put 72-week reductions in the rough range of 15% at 5 mg to 21% at 15 mg, the curve is steepest early and flattens near a year, and individual results vary widely around those means. None of it is a promise, and none of it replaces a clinician. See the full disclaimer before acting on any figure here.